TABLE 1.
bdg interacts with the core tissue polarity genes in overexpression and loss-of-function analyses
| Genotype | A/P (%) | D/V (%) | AP/DV (%) | R3/R3 (%) | R4/R4 (%) | FTR (%) | Total errors (%) | N |
|---|---|---|---|---|---|---|---|---|
| sev-stbm14-1/+ | 5.5 | 6.3 | 0.4 | 1.2 | 2.2 | 0 | 15.5 | 2135 (20) |
| sev-stbm14-1/bdgGMREP*** | 1.2 | 1.5 | 0.2 | 0.3 | 0.3 | 0 | 3.4 | 1892 (20) |
| sev-stbm14-1/bdg164*** | 7.0 | 11.5 | 3.1 | 0.7 | 2.6 | 0.7 | 25.5 | 1537 (13) |
| stbm6cn/stbm6cn | 10.6 | 21.9 | 3.6 | 4.3 | 1.6 | 2.3 | 44.3 | 1328 (12) |
| stbm6cn, bdgGMREP/stbm6cn*** | 12.6 | 27.7 | 2.3 | 1.0 | 1.3 | 0 | 45.0 | 1240 (16) |
| stbm6cn, bdg164/stbm6cn, bdg164*** | 9.7 | 26.3 | 4.5 | 13.8 | 4.9 | 1.7 | 61.1 | 1488 (15) |
| stbm153/stbm153 | 11.3 | 18.6 | 3.0 | 0.4 | 1.4 | 1.5 | 36.2 | 1049 (11) |
| stbm153, bdg164/stbm153, bdg164*** | 8.8 | 12.9 | 3.0 | 23.2 | 4.4 | 1.8 | 53.9 | 799 (8) |
| sev-dsh/+ | 3.4 | 2.3 | 2.4 | 1.9 | 0.6 | 0 | 10.5 | 1006 (9) |
| sev-dsh/bdgGMREP* | 5.0 | 3.8 | 2.6 | 3.7 | 1.6 | 0 | 16.7 | 1336 (11) |
| sev-dsh/bdg164 | 3.0 | 2.6 | 3.5 | 1.0 | 1.0 | 0 | 11.1 | 800 (7) |
| dsh1/Y | 9.4 | 6.3 | 4.9 | 2.2 | 0.6 | 1.3 | 24.7 | 956 (9) |
| dsh1/Y; bdgGMREP/+*** | 14.3 | 11.8 | 6.3 | 3.6 | 5.2 | 1.1 | 42.4 | 441 (5) |
| dsh1/Y; bdg164/+*** | 8.4 | 7.0 | 4.9 | 4.4 | 6.4 | 0.4 | 31.6 | 699 (6) |
| dsh1/Y; bdg164/bdg164*** | 12.9 | 10.3 | 5.4 | 25.6 | 7.0 | 0.8 | 61.9 | 1268 (8) |
| pksple/pksple | 1.1 | 41.5 | 1.9 | 1.6 | 0.8 | 0 | 46.9 | 744 (7) |
| pksple, bdgGMREP/pksple | 2.1 | 39.2 | 1.2 | 0.5 | 0.9 | 0 | 43.9 | 864 (10) |
| pksple, bdg164/pksple, bdg164*** | 2.7 | 31.1 | 1.1 | 9.2 | 3.4 | 0.1 | 47.6 | 818 (9) |
| sev-fmi/Y | 9.7 | 31.9 | 2.2 | 0.7 | 0.4 | 0.6 | 45.6 | 1253 (10) |
| sev-fmi/Y; bdgGMREP/+* | 13.3 | 27.3 | 2.8 | 0.8 | 1.1 | 0.1 | 45.5 | 714 (6) |
| sev-fmi/Y; bdg164/+* | 7.8 | 24.9 | 2.5 | 1.9 | 2.3 | 0.2 | 39.6 | 606 (6) |
| fmifrz3/fmifrz3 | 9.6 | 5.4 | 2.7 | 3.6 | 1.2 | 0.7 | 23.2 | 1073 (12) |
| fmifrz3, bdgGMREP/fmifrz3*** | 13.5 | 23.7 | 4.2 | 2.0 | 0.6 | 0.9 | 44.9 | 801 (9) |
| fmifrz3, bdg164/fmifrz3, bdg164*** | 6.1 | 5.2 | 3.6 | 12.5 | 8.7 | 0 | 35.9 | 473 (6) |
| sev∷dgo2C/+ | 19.6 | 0.8 | 1.4 | 2.8 | 0.4 | 3.0 | 28.1 | 855 (9) |
| sev∷dgo2C; bdgGMREP/+*** | 31.5 | 2.4 | 0.8 | 6.7 | 4.4 | 1.5 | 47.3 | 723 (8) |
| sev∷dgo2C; bdg164/+*** | 18.8 | 1.0 | 0.4 | 10.4 | 3.0 | 3.7 | 37.3 | 789 (8) |
| dgo380/dgo380 | 3.6 | 1.4 | 0.5 | 13.2 | 14.1 | 0.6 | 33.5 | 937 (9) |
| dgo380, bdgGMREP/dgo380*** | 6.3 | 3.2 | 1.1 | 4.3 | 5.0 | 0.1 | 20.0 | 916 (10) |
| dgo380, bdg164/dgo380*** | 2.2 | 0.9 | 0.9 | 8.6 | 5.4 | 0.2 | 18.1 | 778 (9) |
| dgo380, bdg164/dgo380, bdg164 | Lethal | |||||||
| sev-fz/+ | 11.2 | 6.3 | 6.1 | 29.9 | 13.2 | 0 | 66.7 | 839 (9) |
| bdgGMREP/+; sev-fz/+** | 17.1 | 8.1 | 4.6 | 18.8 | 14.6 | 0 | 63.1 | 919 (7) |
| bdg164/+; sev-fz | 10.0 | 7.1 | 4.4 | 32.7 | 12.4 | 0 | 66.6 | 661 (7) |
| fzN21/fzJ22 | 5.6 | 4.9 | 3.1 | 0.1 | 0.3 | 1.5 | 15.6 | 744 (8) |
| bdgGMREP/+; fzN21/fzJ22* | 6.3 | 6.8 | 5.5 | 0.2 | 0.7 | 0.2 | 19.7 | 867 (9) |
| bdg164/+; fzN21/fzJ22 | 5.2 | 4.0 | 1.6 | 0.4 | 0.5 | 0.2 | 11.9 | 965 (10) |
| bdg164/bdg164; fzN21/fzJ22*** | 7.8 | 7.3 | 3.5 | 5.8 | 1.6 | 0.3 | 26.4 | 1180 (7) |
FTR, failure to rotate; N, number of ommatidia scored (eyes scored). Statistical significance is measured by a G-test of independence. The underlined genotype is the reference in each data set. *P-value <10−3; **P-value <10−6; ***P-value <10−9.